Cargando…

Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease

Gut microbiota has been demonstrated to have a significant impact on the initiation, progression and development of complications associated with multiple liver diseases. Notably, nonalcoholic fatty liver diseases, including nonalcoholic steatohepatitis and cirrhosis, severe alcoholic hepatitis, pri...

Descripción completa

Detalles Bibliográficos
Autores principales: Philips, Cyriac Abby, Augustine, Philip, Yerol, Praveen Kumar, Ramesh, Ganesh Narayan, Ahamed, Rizwan, Rajesh, Sasidharan, George, Tom, Kumbar, Sandeep
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132020/
https://www.ncbi.nlm.nih.gov/pubmed/32274349
http://dx.doi.org/10.14218/JCTH.2019.00035
_version_ 1783517366309617664
author Philips, Cyriac Abby
Augustine, Philip
Yerol, Praveen Kumar
Ramesh, Ganesh Narayan
Ahamed, Rizwan
Rajesh, Sasidharan
George, Tom
Kumbar, Sandeep
author_facet Philips, Cyriac Abby
Augustine, Philip
Yerol, Praveen Kumar
Ramesh, Ganesh Narayan
Ahamed, Rizwan
Rajesh, Sasidharan
George, Tom
Kumbar, Sandeep
author_sort Philips, Cyriac Abby
collection PubMed
description Gut microbiota has been demonstrated to have a significant impact on the initiation, progression and development of complications associated with multiple liver diseases. Notably, nonalcoholic fatty liver diseases, including nonalcoholic steatohepatitis and cirrhosis, severe alcoholic hepatitis, primary sclerosing cholangitis and hepatic encephalopathy, have strong links to dysbiosis – or a pathobiological change in the microbiota. In this review, we provide clear and concise discussions on the human gut microbiota, methods of identifying gut microbiota and its functionality, liver diseases that are affected by the gut microbiota, including novel associations under research, and provide current evidence on the modulation of gut microbiota and its effects on specific liver disease conditions.
format Online
Article
Text
id pubmed-7132020
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-71320202020-04-09 Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease Philips, Cyriac Abby Augustine, Philip Yerol, Praveen Kumar Ramesh, Ganesh Narayan Ahamed, Rizwan Rajesh, Sasidharan George, Tom Kumbar, Sandeep J Clin Transl Hepatol Review Article Gut microbiota has been demonstrated to have a significant impact on the initiation, progression and development of complications associated with multiple liver diseases. Notably, nonalcoholic fatty liver diseases, including nonalcoholic steatohepatitis and cirrhosis, severe alcoholic hepatitis, primary sclerosing cholangitis and hepatic encephalopathy, have strong links to dysbiosis – or a pathobiological change in the microbiota. In this review, we provide clear and concise discussions on the human gut microbiota, methods of identifying gut microbiota and its functionality, liver diseases that are affected by the gut microbiota, including novel associations under research, and provide current evidence on the modulation of gut microbiota and its effects on specific liver disease conditions. XIA & HE Publishing Inc. 2019-12-11 2020-03-28 /pmc/articles/PMC7132020/ /pubmed/32274349 http://dx.doi.org/10.14218/JCTH.2019.00035 Text en © 2019 Authors. http://creativecommons.org/licenses/by-nc/4.0/ This article has been published under the terms of Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0), which permits noncommercial unrestricted use, distribution, and reproduction in any medium, provided that the following statement is provided. “This article has been published in Journal of Clinical and Translational Hepatology at DOI: 10.14218/JCTH.2019.00035 and can also be viewed on the Journal’s website at http://www.jcthnet.com”.
spellingShingle Review Article
Philips, Cyriac Abby
Augustine, Philip
Yerol, Praveen Kumar
Ramesh, Ganesh Narayan
Ahamed, Rizwan
Rajesh, Sasidharan
George, Tom
Kumbar, Sandeep
Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title_full Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title_fullStr Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title_full_unstemmed Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title_short Modulating the Intestinal Microbiota: Therapeutic Opportunities in Liver Disease
title_sort modulating the intestinal microbiota: therapeutic opportunities in liver disease
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7132020/
https://www.ncbi.nlm.nih.gov/pubmed/32274349
http://dx.doi.org/10.14218/JCTH.2019.00035
work_keys_str_mv AT philipscyriacabby modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT augustinephilip modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT yerolpraveenkumar modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT rameshganeshnarayan modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT ahamedrizwan modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT rajeshsasidharan modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT georgetom modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease
AT kumbarsandeep modulatingtheintestinalmicrobiotatherapeuticopportunitiesinliverdisease